Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is described in its public communications as a company that owns rights to pharmaceutical royalties and operates as a pharmaceutical royalty company. Its recurring news releases focus on financial results and business updates related to this royalty-based model. Each quarter, the company issues press releases detailing net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses from continuing operations.
These earnings announcements highlight how changes in sales of licensed products by TherapeuticsMD’s licensees affect license revenue, and how the company’s transition from a commercializing pharmaceutical business to a royalty-based business has influenced its cost structure. The company frequently discusses reductions in operating expenses, including lower general and administrative costs, and refers to efficiencies realized as a royalty-based business with more limited infrastructure.
Another recurring theme in TherapeuticsMD’s news is its evaluation of strategic alternatives. In multiple press releases, the company states that it is exploring a variety of potential transactions, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company. It also notes that there can be no assurance of any particular outcome and that no timetable has been set for this process.
Visitors to the TXMD news page can review this sequence of financial updates, commentary on the company’s royalty assets, and disclosures about its strategic review process. For investors and followers of TXMD stock, these news items provide insight into the company’s royalty revenue trends, expense profile, and the status of its exploration of possible strategic alternatives over time.
TherapeuticsMD (NASDAQ: TXMD) has secured a $15 million private investment from Rubric Capital Management to support its operating capital needs. This financing comes alongside an extension of its debt maturity date with Sixth Street Partners to September 30, 2022, with options for further extensions if additional equity of $7 million is raised.
The investment is anticipated to enable the company to continue meeting demand for its women's healthcare products while evaluating strategic options to enhance shareholder value.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced the anticipated termination of its Merger Agreement with EW Healthcare Partners due to the failure to acquire the required majority of shares by the tender offer deadline on July 12, 2022. Consequently, the tender offer has expired, and the Company expects the agreement to terminate following July 13, 2022. Despite this setback, TherapeuticsMD plans to maintain normal operations.
EW Healthcare Partners announced the extension of its tender offer to purchase all outstanding shares of TherapeuticsMD, Inc. (NASDAQ: TXMD) at $10.00 per share, moving the expiration date to July 12, 2022. As of July 5, 2022, approximately 29.2% of TXMD shares had been tendered. The offer is characterized as EW's best and final proposal. TherapeuticsMD previously indicated that without a successful closing of this deal, it might need to file for Chapter 11 bankruptcy protection.
EW Healthcare Partners has launched a cash tender offer for all common stock of TherapeuticsMD (TXMD) at $10.00 per share, representing a significant premium of approximately 211.8% over the 30-day average price and 367.3% over TXMD's price on May 27, 2022. The transaction is valued at around $177 million and follows a merger agreement signed on May 27, 2022. The offer will expire on July 5, 2022, unless extended. Completion is contingent upon shareholder participation and other standard conditions.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced a definitive merger agreement to be acquired by EW Healthcare Partners. Under the agreement, EW Healthcare will offer $10.00 per share for all outstanding TXMD shares, representing a premium of 367.3% over the stock's last closing price on May 27, 2022. The total enterprise value for TXMD is approximately $177 million. The tender offer is set to commence and will be followed by a merger, pending certain conditions. Upon completion, TXMD will become a privately held entity.
TherapeuticsMD (NASDAQ:TXMD) announced FDA approval for a supplemental New Drug Application for ANNOVERA, marking a significant milestone for the company. This approval allows for a reduction in manufacturing batch rejections and an increase in product supply, enabling an additional 7,000 rings to meet short- and long-term demand. Since its initial approval in August 2018, ANNOVERA remains the only FDA-approved, procedure-free, long-lasting reversible birth control option.
TherapeuticsMD (TXMD) reported Q1 2022 net product revenue of $19.3 million, a decrease from $19.9 million in Q1 2021. Despite ANNOVERA experiencing manufacturing challenges, prescriptions rose by 27% to 8,014. The divestiture of vitaCare for $150 million was completed in just five weeks. However, the net loss for the quarter was $49 million, or $5.69 per share. Cash on hand decreased significantly to $30.4 million from $65.1 million at the end of 2021. The company aims for improved performance moving forward.
TherapeuticsMD, Inc. (TXMD) will announce its first quarter 2022 financial results on
TherapeuticsMD (NASDAQ: TXMD) has successfully completed the $150 million divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX). This strategic move, initially announced on March 6, 2022, allows TXMD to concentrate on its women's health portfolio. The company could also receive an additional $7 million based on vitaCare's 2023 financial performance. CEO Hugh O’Dowd emphasized the importance of this transaction in enhancing value for shareholders and patients.
TherapeuticsMD, Inc. (TXMD) has reached a definitive agreement to divest its vitaCare business unit, allowing the company to concentrate on women's healthcare. CEO Hugh O’Dowd stated this move supports their goal to empower women through affordable healthcare solutions. In Q4 2021, TXMD reported total revenue of $18.7 million, down from $22.6 million in Q4 2020, driven by decreased sales of ANNOVERA and IMVEXXY. Net loss for the quarter was $43 million, or $0.10 per share. The company amended credit terms to enhance financial flexibility. Conference call scheduled for 8:30 a.m. ET today.